News
Polypill demonstrates encouraging results in reducing risk factors for heart attack and stroke. An all-in-one treatment that could potentially save tens of thousands of lives could be available in the UK within the next two…
Novartis’ second quarter results show the healthcare company’s significant regulatory milestones and prove it is on track to deliver 2012 outlook. By the looks of Novartis’ second quarter profit results it is clear the healthcare company is well-positioned to continue delivering…
The FDA approves its second weight-loss drug in a few weeks to help tackle the growing obesity epidemic in America. The FDA has announced it has approved a new weight-loss drug, called Qsymia, expanding the range…
US-based generic-drug maker, Par Pharmaceutical, has agreed to be acquired by TPG Capital. Private equity-firm, TPG Capital, has entered into a definitive agreement to acquire US-based Par Pharmaceutical…
UK’s NICE has launched a new advisory service entitled Evidence summaries: new medicines to provide information and support for the NHS and patients in England. The National Institute for Health and Clinical Excellence (NICE) has launched a new service to provide high quality information to…
GSK is to acquire HGS for US $14.25 share in cash, equalling a transaction value of HGS at US $3.6 billion. GlaxoSmithKline has announced it has entered an agreement with Human Genome Sciences (HGS), under which…
GSK launches TV and print advertising campaign, supporting the biggest anti-doping operation in the history of the Olympics Games. Global pharmaceutical company, GlaxoSmithKline, has formally marked its role as Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games…
New report says that the emerging markets’ spending on medicines will nearly double in growth over the next five years, while the developed economies will experience slow growth due to budget pressures. The global market for medicines is set to rebound from an expected low point of 3 – 4 % growth in 2012 to…
US judge dismisses AstraZeneca’s bid to overturn FDA’s approval to allow generic versions of its antipsychotic drug, Seroquel. AstraZeneca’s bid to block the US Food and Drug Administation’s (FDA) approval of generic versions of its antipsychotic drug, Seroquel, has been…
